Compare GRRRW & BCTXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GRRRW | BCTXL |
|---|---|---|
| Founded | N/A | N/A |
| Country | United Kingdom | Canada |
| Employees | N/A | 4 |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2022 | 2025 |
| Metric | GRRRW | BCTXL |
|---|---|---|
| Price | $0.15 | $1.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 21.0K | 11.6K |
| Earning Date | 04-04-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $0.61 |
| 52 Week High | $0.79 | $1.40 |
| Indicator | GRRRW | BCTXL |
|---|---|---|
| Relative Strength Index (RSI) | 43.53 | 57.09 |
| Support Level | $0.11 | $0.92 |
| Resistance Level | $0.35 | $1.14 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 31.00 | 73.44 |
Gorilla Technology Group Inc is engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments. Its expertise lies in revolutionizing urban operations, enhancing security, and optimizing digital transformation. It delivers pioneering products that integrate AI, deep learning, and edge computing to advance intelligent video surveillance, facial recognition, license plate recognition, post-event analytics, cybersecurity, and network intelligence.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.